Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.

van Zyl-Smit RN, Esmail A, Bateman ME, Dawson R, Goldin J, van Rikxoort E, Douoguih M, Pau MG, Sadoff JC, McClain JB, Snowden MA, Benko J, Hokey DA, Rutkowski KT, Graves A, Shepherd B, Ishmukhamedov S, Kagina BMN, Abel B, Hanekom WA, Scriba TJ, Bateman ED.

Am J Respir Crit Care Med. 2017 May 1;195(9):1171-1180. doi: 10.1164/rccm.201603-0654OC.

PMID:
28060545
2.

A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Hokey DA, Wachholder R, Darrah PA, Bolton DL, Barouch DH, Hill K, Dheenadhayalan V, Schwander S, Godin CS, Douoguih M, Pau MG, Seder RA, Roederer M, Sadoff JC, Sizemore D.

Hum Vaccin Immunother. 2014;10(8):2199-210. doi: 10.4161/hv.29108.

3.

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.

Kagina BM, Tameris MD, Geldenhuys H, Hatherill M, Abel B, Hussey GD, Scriba TJ, Mahomed H, Sadoff JC, Hanekom WA; 018-402 Clinical Lab study team, Mansoor N, Hughes J, de Kock M, Whatney W, Africa H, Krohn C, Veldsman A, Kany AL, Douoguih M, Pau MG, Hendriks J, McClainc B, Benko J, Snowden MA, Hokey DA.

Vaccine. 2014 Oct 14;32(45):5908-17. doi: 10.1016/j.vaccine.2014.09.001. Epub 2014 Sep 10.

PMID:
25218194
4.

Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Darrah PA, Bolton DL, Lackner AA, Kaushal D, Aye PP, Mehra S, Blanchard JL, Didier PJ, Roy CJ, Rao SS, Hokey DA, Scanga CA, Sizemore DR, Sadoff JC, Roederer M, Seder RA.

J Immunol. 2014 Aug 15;193(4):1799-811. doi: 10.4049/jimmunol.1400676. Epub 2014 Jul 14.

5.

Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.

Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA.

Am J Respir Crit Care Med. 2013 Aug 15;188(4):492-502. doi: 10.1164/rccm.201208-1385OC.

6.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

7.

Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.

Hopkins R, Bridgeman A, Bourne C, Mbewe-Mvula A, Sadoff JC, Both GW, Joseph J, Fulkerson J, Hanke T.

Eur J Immunol. 2011 Dec;41(12):3542-52. doi: 10.1002/eji.201141962. Epub 2011 Oct 26.

8.

Genetic immunization in the lung induces potent local and systemic immune responses.

Song K, Bolton DL, Wei CJ, Wilson RL, Camp JV, Bao S, Mattapallil JJ, Herzenberg LA, Herzenberg LA, Andrews CA, Sadoff JC, Goudsmit J, Pau MG, Seder RA, Kozlowski PA, Nabel GJ, Roederer M, Rao SS.

Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22213-8. doi: 10.1073/pnas.1015536108. Epub 2010 Dec 6. Erratum in: Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2629. Wei, Chih-Jen [added].

9.

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.

Rosario M, Fulkerson J, Soneji S, Parker J, Im EJ, Borthwick N, Bridgeman A, Bourne C, Joseph J, Sadoff JC, Hanke T.

J Virol. 2010 Aug;84(15):7815-21. doi: 10.1128/JVI.00726-10. Epub 2010 May 19.

10.

Update on research and development pipeline: tuberculosis vaccines.

Beresford B, Sadoff JC.

Clin Infect Dis. 2010 May 15;50 Suppl 3:S178-83. doi: 10.1086/651489. Review.

PMID:
20397946
11.

Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.

Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, Joseph J, Douek DC, Greenaway HY, Venturi V, Gostick E, Price DA, Both GW, Sadoff JC, Hanke T.

J Virol. 2010 Jun;84(12):5898-908. doi: 10.1128/JVI.02607-09. Epub 2010 Apr 7.

12.

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.

Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, de Kock M, van der Merwe L, Hawkridge A, Veldsman A, Hatherill M, Schirru G, Pau MG, Hendriks J, Weverling GJ, Goudsmit J, Sizemore D, McClain JB, Goetz M, Gearhart J, Mahomed H, Hussey GD, Sadoff JC, Hanekom WA.

Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17. doi: 10.1164/rccm.200910-1484OC. Epub 2010 Feb 18.

13.

Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques.

Bonaldo MC, Martins MA, Rudersdorf R, Mudd PA, Sacha JB, Piaskowski SM, Costa Neves PC, Veloso de Santana MG, Vojnov L, Capuano S 3rd, Rakasz EG, Wilson NA, Fulkerson J, Sadoff JC, Watkins DI, Galler R.

J Virol. 2010 Apr;84(7):3699-706. doi: 10.1128/JVI.02255-09. Epub 2010 Jan 20.

14.

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.

Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, Cantarero L, Basaraba RJ, Bang P, Kromann I, McMclain JB, Sadoff JC, Andersen P.

Vaccine. 2010 Jan 22;28(4):1084-93. doi: 10.1016/j.vaccine.2009.10.114. Epub 2009 Nov 5.

PMID:
19896449
15.

Tuberculosis vaccine research: the impact of immunology.

Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC.

Curr Opin Immunol. 2009 Jun;21(3):331-8. doi: 10.1016/j.coi.2009.05.017. Epub 2009 Jun 7. Review.

PMID:
19505813
16.

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.

Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga C, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, Sadoff JC.

Vaccine. 2009 Jul 16;27(33):4412-23. doi: 10.1016/j.vaccine.2009.05.048. Epub 2009 Jun 2.

PMID:
19500523
17.

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, Sadoff JC, Horwitz MA.

J Infect Dis. 2008 Nov 15;198(10):1491-501. doi: 10.1086/592450.

18.

Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses.

Zvi A, Ariel N, Fulkerson J, Sadoff JC, Shafferman A.

BMC Med Genomics. 2008 May 28;1:18. doi: 10.1186/1755-8794-1-18.

19.

Correlates, surrogates, and vaccines.

Sadoff JC, Wittes J.

J Infect Dis. 2007 Nov 1;196(9):1279-81. Epub 2007 Oct 2. No abstract available.

PMID:
17922389
20.

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J.

Infect Immun. 2007 Aug;75(8):4105-15. Epub 2007 May 25.

21.

Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis.

Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ.

Genes Immun. 2007 Jun;8(4):334-43. Epub 2007 Apr 12.

PMID:
17429413
22.

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.

Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, Goepfert PA, Mulligan MJ, Kalams SA, Rinaldo C, Zhu L, Cox KS, Guan L, Long R, Persaud N, Caulfield MJ, Sadoff JC, Emini EA, Thaler S, Shiver JW.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):67-76.

PMID:
17263635
23.

Advances in tuberculosis vaccine strategies.

Skeiky YA, Sadoff JC.

Nat Rev Microbiol. 2006 Jun;4(6):469-76. Review.

PMID:
16710326
24.

Vaccine risk and benefit in the developing world.

Sadoff JC.

Health Aff (Millwood). 2005 Sep-Oct;24(5):1379-80. No abstract available.

PMID:
16162591
25.

The role of "go no-go" decisions in TB vaccine development.

Sadoff JC, Hone D.

Microbes Infect. 2005 May;7(5-6):899-904. Epub 2005 Apr 14.

PMID:
15878835
26.

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.

Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M, Hovi T, Eskola J, Käyhty H, Bohidar N, Sadoff JC, Mäkelä PH; Finnish Otitis Media Study Group.

Clin Infect Dis. 2003 Nov 1;37(9):1155-64. Epub 2003 Oct 7.

PMID:
14557958
27.

A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.

Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, Lin TY, Lee BW, Kwan K, Kasim SM, Chan CY, Kaplan KM, Distefano DJ, Harmon AL, Golie A, Hartzel J, Xu J, Li S, Matthews H, Sadoff JC, Shaw A.

Vaccine. 2002 Jul 26;20(23-24):2942-9.

PMID:
12126906
28.

Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.

Li S, Chan IS, Matthews H, Heyse JF, Chan CY, Kuter BJ, Kaplan KM, Vessey SJ, Sadoff JC.

Pediatr Infect Dis J. 2002 Apr;21(4):337-42.

PMID:
12075766
29.

Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy.

Vessey SJ, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, Carfagno PA, Sadoff JC, Heyse JF, Matthews H, Li S, Chan IS.

J Pediatr. 2001 Aug;139(2):297-304.

PMID:
11487760
30.

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR, et al.

J Infect Dis. 1998 Jun;177(6):1664-73.

PMID:
9607847
31.

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M.

Crit Care Med. 1997 Jul;25(7):1115-24.

PMID:
9233735
32.

Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization.

Sizemore DR, Branstrom AA, Sadoff JC.

Vaccine. 1997 Jun;15(8):804-7.

PMID:
9234519
33.

Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Hib-HB Vaccine Study Group.

West DJ, Hesley TM, Jonas LC, Feeley LK, Bird SR, Burke P, Sadoff JC.

Pediatr Infect Dis J. 1997 Jun;16(6):593-9.

PMID:
9194110
34.

Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia.

Nosten F, Luxemburger C, Kyle DE, Gordon DM, Ballou WR, Sadoff JC, Brockman A, Permpanich B, Chongsuphajaisiddhi T, Heppner DG.

Am J Trop Med Hyg. 1997 May;56(5):526-32.

PMID:
9180603
35.

Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group.

Sprung CL, Eidelman LA, Pizov R, Fisher CJ Jr, Ziegler EJ, Sadoff JC, Straube RC, McCloskey RV.

Crit Care Med. 1997 Mar;25(3):383-7. Erratum in: Crit Care Med 1997 Jun;25(6):1092.

PMID:
9118650
36.

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB.

Lancet. 1997 Jan 18;349(9046):155-9.

PMID:
9111538
37.

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.

Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, Sadoff JC, Eckels KH.

J Infect Dis. 1996 Dec;174(6):1176-84.

PMID:
8940206
38.

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, Orr N, Taylor DN, Sadoff JC, Chu C, Shiloach J, Schneerson R, Robbins JB.

Infect Immun. 1996 Oct;64(10):4074-7.

39.

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group.

Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC, Heppner DG.

Lancet. 1996 Sep 14;348(9029):701-7.

PMID:
8806288
40.

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, De Taisne C, Hui GS, Chang SP, Church P, Hollingdale MR, Kaslow DC, Hoffman S, Guito KP, Ballou WR, Sadoff JC, Paoletti E.

Infect Immun. 1996 Sep;64(9):3833-44.

41.

DNA vaccines.

Ulmer JB, Sadoff JC, Liu MA.

Curr Opin Immunol. 1996 Aug;8(4):531-6. Review.

PMID:
8794021
42.

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes.

Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W, Krzych U, Schneider I, Wirtz RA, Richards RL, Trofa A, Hall T, Sadoff JC, Boerger P, Alving CR, Sylvester DR, Porter TG, Ballou WR.

J Infect Dis. 1996 Aug;174(2):361-6.

PMID:
8699067
43.

Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States.

Gordon DM, Duffy PE, Heppner DG, Lyon JA, Williams JS, Scheumann D, Farley L, Stacey D, Haynes JD, Sadoff JC, Ballou WR.

Am J Trop Med Hyg. 1996 Jul;55(1):63-8.

PMID:
8702024
44.

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E.

N Engl J Med. 1996 Jun 27;334(26):1697-702.

45.

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.

Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, Strickland GT, Gordon DM, Ballou WR, Bales JD Jr, Wirtz RA, Wittes J, Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC.

Vaccine. 1996 Jun;14(8):817-27.

PMID:
8817830
46.

Sialylation lessens the infectivity of Neisseria gonorrhoeae MS11mkC.

Schneider H, Schmidt KA, Skillman DR, Van De Verg L, Warren RL, Wylie HJ, Sadoff JC, Deal CD, Cross AS.

J Infect Dis. 1996 Jun;173(6):1422-7.

PMID:
8648215
47.

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

Bhattacharjee AK, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger WD, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS.

J Infect Dis. 1996 May;173(5):1157-63.

PMID:
8627067
48.

Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Lanar DE, Tine JA, de Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC.

Infect Immun. 1996 May;64(5):1666-71.

49.

A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.

Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM.

Vaccine. 1995 Nov;13(16):1488-94.

PMID:
8578831
50.

Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization.

Sizemore DR, Branstrom AA, Sadoff JC.

Science. 1995 Oct 13;270(5234):299-302.

PMID:
7569980

Supplemental Content

Loading ...
Support Center